

# Curriculum Vitae

## Kyle J. Smith, MD

### Practice

---

- 2009-Present Tyler Cardiac and Endovascular Center  
1769 Troup Hwy, Tyler, TX
- 2009-Present Cardiovascular Associates of East Texas, P.A., Tyler, Texas

### Affiliation

---

- 2009-Present CAET - Research  
1761 Troup Hwy, Tyler, Texas
- 1/1/13-4/26/13 TAD Clinical Research  
1741 Troup Hwy, Tyler, Texas

### Education

---

- 7/1998-5/2002 University of Texas School of Medicine at San Antonio  
San Antonio, Texas  
Doctor of Medicine
- 8/1993-5/1997 University of Texas at Austin  
Austin, Texas  
Bachelor of Science (Major: Biology-High Honors)

#### Post-Graduate Education

- 7/2008-6/2009 Texas A&M University Health Science Center/Scott & White Hospital,  
Interventional Cardiology Fellowship
- 7/2005-6/2008 Texas A&M University Health Science Center/Scott & White Hospital  
Cardiovascular Disease Fellowship
- 6/2002-6/2005 Wake Forest University Baptist Medical Center  
Internal Medicine Residency and Internship

## **Board Certification**

---

2009	American Board of Internal Medicine, Interventional Cardiology
2008	American Board of Internal Medicine, Cardiovascular disease
2008	Nuclear Cardiology Board Certification
2005	American Board of Internal Medicine, Internal Medicine

## **Licensure**

---

2005	State of Texas #M2117
------	-----------------------

## **Hospital Appointments**

---

East Texas Medical Center, Tyler, Texas

East Texas Medical Center, Athens, Texas

East Texas Medical Center, Fairfield, Texas

East Texas Medical Center, Carthage, Texas

East Texas Medical Center, Pittsburg, Texas

Trinity Mother Frances Hospital, Tyler, Texas

## **Administrative Appointments**

---

2015	President of Smith County Medical Society
2011-Present	Medical Director of Research Cardiovascular Associates of East Texas

## **Research**

---

Co-Investigator – ABLATE. The trial is a prospective, multi-center, non-randomized registry evaluating the safety and effectiveness of Excimer Laser Atherectomy (ELA) using the Spectranetics Turbo-Elite Laser Ablation Catheter.

Co-Investigator – MIMICS-2. Evaluation of Safety and Efficacy of the BioMimics 3DTM Stent System in the Femoropopliteal Arteries of Patients with Symptomatic Peripheral Arterial Disease.

Co-Investigator - DECLARE - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.

Co-Investigator - ABSORB III - Randomized Controlled Trial. A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the treatment of Subjects with de novo Native coronary Artery Lesions.

Co-Investigator - AD HOC PCI - A randomized, open-label, multiple-center, parallel group, study to compare the platelet inhibition with Verify Now™ assay of ticagrelor vs. clopidogrel in troponin negative Acute Coronary Syndrome (ACS) subjects undergoing Ad Hoc percutaneous coronary intervention (PCI)

Co-Investigator - EXCITE - Excimer laser randomized Controlled study for treatment of femoropopliteal In-Stent Restenosis.

Co-Investigator - EUCLID -A randomized, double-blind, parallel group, multicenter phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic stroke in patients with established Peripheral Artery Disease (EUCLID – Examining Use of tiCagreLor In paD)

Co-Investigator – PARADIGM - A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction.

Primary Investigator - TAO: "A randomized, double-blind, triple-dummy trial to compare the efficacy of otamixaban with Unfractionated Heparin + eptifibatide, in patients with Unstable angina/Non ST segment Elevation Myocardial infarction scheduled to undergo an early invasive strategy"

Co-Investigator - Taxus Libertē "A prospective, multi-center study designed to observe clinical outcomes in patient receiving the TAXUS Libertē-Paclitaxel-Eluting Coronary Stent and prasugrel as part of a dual antiplatelet therapy drug regimen"

Co-Investigator – RESOLUTE – A Clinical Evaluation of the Medtronic Endeavor® Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of *De Novo* Lesions in Native Coronary Arteries with a Reference Vessel Diameter of 2.25 mm to 4.2 mm.

Co-Investigator – ENDEAVOR SVS – A Clinical Evaluation of the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment of *De novo* Lesions in Small Diameter Native Coronary Arteries.

Principal Investigator – The Complete® SE SFA Study: The Medtronic Complete Self-Expanding(SE) SFA Stent for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery

Co-Investigator - VISTA-16 Evaluation of the Safety and Efficacy of Short-term A-002 Treatment in Subjects with Acute Coronary Syndromes.

## Honors and Awards

---

### *Undergraduate*

Phi Beta Kappa, 1997  
College of Natural Sciences Academic Excellence Award Winner, 1997  
Golden Key National Honor Society, 1996-1997  
Order of Omega Honor Society, 1996-1997  
Beta Beta Beta Biological Honor Society, 1996-1997

## Volunteer Experience

---

Church Missions Work in Moscow, Russia  
Inner-City Church Ministry Work in Queens, New York City

## Language

---

Intermediate-Level Spanish

## Publications

---

**Smith KJ**, Call JT, Sane DC. Case Studies of HIT in Cardiovascular Medicine. Seminars in Thrombosis and Hemostasis 2004 June; 30(3):285-89.

**Smith KJ**, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovascular Research 2003 Sep 1;59(3):538-48.

Dehmer GJ, **Smith KJ**, Drug-eluting coronary artery stents, American Family Physician. 2009 Dec 1; 90(11): 1245-51